Faeth Therapeutics grants performance options to employees; CEO receives 398,018 shares tied to $70 stock price hurdle

Sensei Biotherapeutics, Inc.

CEO Anand Parikh granted 398,018 performance-based stock options; exercise price equals grant-date closing price.
Options vest in a single tranche when 30-day average closing price reaches $70.00 within 4 years, or upon change in control with ≥$70 per share consideration.
General Counsel Christopher Gerry and SVP Finance Josiah Craver each received options (84,766 and 30,824, respectively); both no longer classified as executive officers as of June 2026.
If the stock price hurdle is not met within the performance period or upon termination of service, all performance options are forfeited.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.